Donna Ambrosino, M.D.

Talk Title: Correlates of Protection and COVID-19 Vaccines

Donna Ambrosino, M.D., has had a career for over 35 years as a scientific leader for biologics and vaccine development. Most recently she has served as an independent consultant to CEPI regarding development of COVID-19 vaccines having previously advised WHO during the SARS 2003 epidemic and on-site assessment of vaccine companies in China. In addition, she is a member of the Correlates Working Group of the Gates Foundation, a member of the Scientific Advisory Boards of Clover Biopharmaceuticals, Everest Medicines, Vaxxinity and Senda, and on the Board of Directors of Inventprise.
 
Until November 2019, she was CEO of Nosocomial Vaccine Corporation leading the collaborative discovery and development of a gram-negative vaccine for hospital acquired infections. Previously, she served as the first CEO of MassBiologics, the only non-profit FDA licensed vaccine and biologic manufacturer in the U.S. There as Professor of Pediatrics UMass Chan Medical School, she recruited and led the scientific team that discovered multiple monoclonal antibodies targeted to infectious disease pathogens with three products reaching late stage development with two now commercially available for prevention of C.difficile Disease and Rabies (Zinplava and RabiShield). Before MassBiologics, Dr. Ambrosino was Associate Professor of Pediatrics at Dana-Farber Cancer Institute and Children’s Hospital in Boston MA for 19 years. There, she was a National Institutes of Health-funded researcher and an internationally recognized expert in infectious diseases, vaccine immunology and vaccine clinical trial design. She is a graduate of Harvard University, Summa Cum Laude and Dartmouth Medical School.